2017

October 05, 2017
Apogenix Granted Orphan Designation by the European Commission for Asunercept to Treat Myelodysplastic Syndromes

May 29, 2017
Apogenix Granted PRIME Designation by European Medicines Agency for Asunercept to Treat Glioblastoma

April 26, 2017
Apogenix to Present at Three Upcoming International Conferences

April 11, 2017
Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie

March 20, 2017
Apogenix Presents Data on Novel Hexavalent TNF Receptor Agonists (HERA) at the Upcoming Annual Meeting of the American Association for Cancer Research (AACR)

2016

December 05, 2016
Apogenix Reports Final Phase I MDS Data at this Year´s American Society of Hematology (ASH) Meeting 

November 04, 2016
Apogenix Reports Significant Progress in Collaboration with CANbridge

November 03, 2016
Apogenix Announces Oral Presentation on APG101 at Upcoming 58th American Society of Hematology (ASH) Meeting & Exposition

July 19, 2016
Apogenix Granted European Patent for the Use of APG101 in the Treatment of Myelodysplastic Syndromes

June 15, 2016
Apogenix Reports Topline Results from Phase I Trial in Myelodysplastic Syndromes with APG101

May 4, 2016
Apogenix to Present at Two Upcoming International Conferences

March 24, 2016
Preclinical Efficacy Data of Apogenix' APG101 in Myelodysplastic Syndromes (MDS) published in Oncotarget

February 16, 2016
Apogenix Receives €3 Million Grant for the Development of a Companion Diagnostic Test for Lead Immuno-Oncology Candidate APG101

January 14, 2016
Apogenix Strengthens U.S. Patent Position for Lead Immuno-Oncology Candidate APG101

January 7, 2016
Apogenix Receives First Milestone Payment from CANbridge Licensing Agreement and Signs Amendment to Include Taiwan
 

2015

December 15, 2015
Apogenix to Present at J.P. Morgan Healthcare Conference

October 13, 2015
Apogenix to Present at Three Upcoming International Conferences

July 28, 2015
Apogenix Enters into Cooperation with R-Biopharm to Develop Companion Diagnostic Tests for Immuno-Oncology Candidate APG101

July 15, 2015
Apogenix Enters into Licensing Agreement with CANbridge Life Sciences for Immuno-Oncology Candidate APG101 in China 

June 3, 2015
Apogenix appoints Peter Willinger as new CFO

June 1, 2015
Apogenix to present at Jefferies 2015 Global Healthcare Conference
 

2014

October 28, 2014
Apogenix – Positive Results from APG101 Phase II Clinical Trial Published in Clinical Cancer Research

January 13, 2014
Apogenix' APG101 Demonstrates Significant Prolongation of Overall Survival in Biomarker-Positive Patients in Phase II Trial for the Treatment of Recurrent Glioblastoma

January 7, 2014
Apogenix to Present Phase II Results with APG101 for the Treatment of Recurrent Glioblastoma at Biotech Showcase in San Francisco
 

 

For press releases from previous years, please visit our archive.

 

Contact Unterseite

Apogenix AG


Address:
Im Neuenheimer Feld 584
69120 Heidelberg
Germany

E-Mail:
contact@apogenix.com
Phone:
+49 (0) 6221 58608 0
Fax:
+49 (0) 6221 58608 10

We welcome your feedback! Please contact us directly: